Formulating clinical strategies for angiotensin antagonism: A review of preclinical and clinical studies

American Journal of Medicine

Volumn 110, Issue 6, 2001, Pages 471-480

  Tabibiazar, Raymond ^a   Jamali, Aamer H ^a   Rockson, Stanley G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; LOSARTAN; NITRIC OXIDE; QUINAPRIL; RENIN; VALSARTAN;

ANIMAL EXPERIMENT; BIOLOGY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DECISION MAKING; DIABETES MELLITUS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HYPOTHESIS; ISCHEMIC HEART DISEASE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; VASCULARIZATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035870787     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00641-6     Document Type: Review

References (92)

1. Gibbons GH, Pfeffer MA. The role of angiotensin in cardiovascular disease: pathophysiologic insights and therapeutic implications. E. Topol, Ed. In: Textbook of Cardiovascular Medicine Updates. Vol 1. NJ: Lippincott Williams & Wilkins Healthcare; 1998:1-12.
2. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153.
3. Drexler H. Hypertension, heart failure, and endothelial function. Am J Cardiol. 82:1998;20S-22S.
4. Mombouli J.V., Vanhoutte P.M. Endothelial dysfunction from physiology to therapy . J Mol Cell Cardiol. 31:1999;61-74.
5. Kim H.S., Krege J.H., Kluckman K.D., et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA. 92:1995;2735-2739.
6. Smithies O., Maeda N. Gene targeting approaches to complex genetic diseases atherosclerosis and essential hypertension . Proc Natl Acad Sci USA. 92:1995;5266-5272.
7. Ito M., Oliverio M.I., Mannon P.J., et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA. 92:1995;3521-3525.
8. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 153:1993;937-942.
9. Danser A.H., Schalekamp M.A., Bax W.A., et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 92:1995;1387-1388.
10. Ueda S., Meredith P.A., Morton J.J., et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 98:1998;2148-2153.
11. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644.
12. Beohar N., Damaraju S., Prather A., et al. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Invest Med. 43:1995;275-280.
13. Pinto Y.M., van Gilst W.H., Kingma J.H., Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol. 25:1995;1622-1626.
14. Dakik H.A., Mahmarian J.J., Verani M.S., et al. Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol. 29:1997;1468-1473.
15. Celentano A., Mancini F.P., Crivaro M., et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol. 83:1999;1196-1200.
16. Montgomery H.E., Clarkson P., Dollery C.M., et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 96:1997;741-747.
17. Amant C., Bauters C., Bodart J.C., et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation. 96:1997;56-60.
18. Kokkonen J.O., Saarinen J., Kovanen P.T. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation. 95:1997;1455-1463.
19. Wright J.W., Harding J.W. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regulatory Peptides. 59:1995;269-295.
20. Unger T., Chung O., Csikos T., et al. Angiotensin receptors. J Hypertens. 14:(suppl):1996;95-103.
21. Pitt B., Konstam M.A. Overview of angiotensin II-receptor antagonists. Am J Cardiol. 82:1998;47S-49S.
22. Bartunek J., Weinberg E.O., Tajima M., et al. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation. 99:1999;22-25.
23. Liu Y.H., Yang X.P., Sharov V.G., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 99:1997;1926-1935.
24. Tamura T., Said S., Harris J., et al. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation. 102:2000;253-259.
25. Briand S.I., Bellemare J.M., Bernier S.G., Guillemette G. Study on the functionality and molecular properties of the AT4 receptor. Endocrine Res. 24:1998;315-323.
26. Kramar E.A., Harding J.W., Wright J.W. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regulatory Peptides. 68:1997;131-138.
27. Kim S., Izumi Y., Yano M., et al. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation. 97:1998;1731-1737.
28. Potter D.D., Sobey C.G., Tompkins P.K., et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 98:1998;800-807.
29. Itoh H., Mukoyama M., Pratt R.E., et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 91:1993;2268-2274.
30. Lindpaintner K., Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circulation Res. 68:1991;905-921.
31. Harrap S.B., Dominiczak A.F., Fraser R., et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation. 93:1996;1148-1154.
32. Taniyama Y., Morishita R., Nakagami H., et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation. 102:2000;246-252.
33. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118.
34. Gainer J.V., Morrow J.D., Loveland A., et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 339:1998;1285-1292.
35. Squire I., Okane K., Anderson N., Reid J. Bradykinin B2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension. 36:2000;132-136.
36. Vaughan D.E. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition. Clin Cardiol. 20:(suppl 2):1997;34-37.
37. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity metabolic effects in hypertension, diabetes, and heart failure . J Cardiovasc Pharmacol. 20:(suppl 11):1992;38-44.
38. Tomiyama H., Kushiro T., Abeta H., et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 23:1994;450-455.
39. Ura N., Higashiura K., Shimamoto K. The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology. 44:1999;153-159.
40. Nakagawa H., Daihara M., Tamakawa H., et al. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol. 34:1999;28-33.
41. Berkenboom G., Langer I., Carpentier Y., et al. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins a bradykinin-dependent mechanism . Hypertension. 30:1997;371-376.
42. Wirth K.J., Linz W., Wiemer G., Scholkens B.A. Kinins and cardioprotection. Pharmacolog Res. 35:1997;527-530.
43. Wiemer G., Linz W., Hatrik S., et al. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension. 30:1997;1183-1190.
44. Linz W., Wiemer G., Scholkens B.A. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol. 80:1997;118A-123A.
45. Emanueli C., Maestri R., Corradi D., et al. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation. 100:1999;2359-2365.
46. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circulation Res. 74:1994;1141-1148.
47. Swedberg K., Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . Am J Cardiol. 62:1988;60A-66A.
48. Sharpe D.N., Murphy J., Coxon R., Hannan S.F. Enalapril in patients with chronic heart failure a placebo-controlled, randomized, double-blind study . Circulation. 70:1984;271-278.
49. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 2:1983;755-763.
50. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
51. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691. [Published erratum appears in N Engl J Med. 1992;327:1768.].
52. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691. [Published erratum appears in N Engl J Med. 1992;327:1768.].
53. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
54. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
55. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 327:1992;669-677.
56. Warner J.G. Jr, Metzger D.C., Kitzman D.W., et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 33:1999;1567-1572.
57. Crozier I., Ikram H., Awan N., et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation. 91:1995;691-697.
58. Gottlieb S.S., Dickstein K., Fleck E., et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 88:1993;1602-1609.
59. Havranek E.P., Thomas I., Smith W.B., et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 33:1999;1174-1181.
60. Riegger G.A., Bouzo H., Petr P., et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation. 100:1999;2224-2230. [in process citation].
61. Parker A.B., Azevedo E.R., Baird M.G., et al. ARCTIC assessment of haemodynamic response in patients with congestive heart failure to telmisartan. A multicentre dose-ranging study in Canada . Am Heart J. 138:1999;843-848.
62. Lang R.M., Elkayam U., Yellen L.G., et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 30:1997;983-991.
63. Dickstein K., Chang P., Willenheimer R., et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 26:1995;438-445.
64. Guazzi M., Melzi G., Agostoni P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 80:1997;1572-1576.
65. Mazayev V.P., Fomina I.G., Kazakov E.N., et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol. 65:1998;239-246.
66. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure randomized trial - the Losartan Heart Failure Survival Study ELITE II . Lancet. 355:2000;1582-1587.
67. Pepine C.J. Rationale for ACE inhibition as an anti-ischaemic therapy. Eur Heart J. 19:(suppl G):1998;34-40.
68. Remme W.J. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs. 54:(suppl 5):1997;59-70.
69. Pfeffer M, McMurray J, Leizorovicz A, et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J. 2000;140:727-750.
70. Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan . Am J Cardiol. 83:1999;477-481.
71. Schlueter W., Keilani T., Batlle D.C. Metabolic effects of converting enzyme inhibitors focus on the reduction of cholesterol and lipoprotein(a) by fosinopril . Am J Cardiol. 72:1993;37H-44H.
72. Lerch M., Teuscher A.U., Beissner P., et al. Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol. 31:1998;576-580.
73. Mancini G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation. 94:1996;258-265.
74. Schiffrin E., Park J., Intengan H., Touyz R. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 101:2000;1653-1659.
75. Prasad A., Tupas-Habib T., Schenke W., et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 101:2000;2349-2354.
76. Anderson T.J., Elstein E., Haber H., Charbonneau F. Comparative study of ACE inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 35:2000;60-66.
77. Dominguez L.J., Barbagallo M., Kattah W., et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens. 8:1995;808-814.
78. Ritz E. Nephropathy in type 2 diabetes. J Intern Med. 245:1999;111-126.
79. Kohzuki M., Yasujima M., Liu P.F., et al. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin Exp Pharmacol Physiol. 1:(suppl 7):1995;366-367.
80. Remuzzi A., Perico N., Amuchastegui C.S., et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 4:1993;40-49.
81. Yotsumoto T., Naitoh T., Shikada K., Tanaka S. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jpn J Pharmacol. 75:1997;59-64.
82. Andersen S., Tarnow L., Rossing P., et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 57:2000;601-606.
83. Mogyorosi A., Sonkodi S. AT1 receptor antagonists a challenge for ACE inhibitors in diabetic nephropathy . Diabetes Metab Res Rev. 15:1999;55-58.
84. Hebert L.A., Falkenhain M.E., Nahman N.S. Jr, et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol. 19:1999;1-6.
85. Fogari R., Zoppi A., Corradi L., et al. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol. 46:1998;467-471.
86. Higashiura K., Ura N., Takada T., et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose- fed rats. Am J Hypertens. 13:2000;290-297.
87. Carvalho C.R., Thirone A.C., Gontijo J.A., et al. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes. 46:1997;1950-1957.
88. Strawn W.B., Chappell M.C., Dean R.H., et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 101:2000;1586-1593.
89. Sato M., Engelman R.M., Otani H., et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker implication of bradykinin-dependent and bradykinin-independent mechanisms . Circulation. 102:(suppl 3):2000;346-351.
90. Goodfield N.E., Newby D.E., Ludlam C.A., Flapan A.D. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation. 99:1999;2983-2985.
91. Cohn JN, Tognoni G. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2000;102:2672-b.
92. Stys T., Lawson W.E., Smaldone G.C., Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med. 160:2000;1409-1413.